Restrategizing Is No Longer an Option
So far, the first quarter of 2009 has been full of initiatives that call for, if not push for, change in the pharmaceutical industry and in medical science overall. Some may say it started when Obama took office. Within six weeks of leading the country, he announced $1.1 billion for comparative effectiveness research. Then, his proposed FY 2010 budget included support for a regulatory pathway for follow-on biologics. And this week, he reversed the ban on the use of federal funding for stem-cell research.
The wait may soon be over for US Food and Drug Administration employees wondering who their new boss will be. President Obama is expected to introduce Governor Kathleen Sebelius of Kansas today as his new nominee for secretary of the US Department of Health and Human Services.
As the pieces of President-Elect Barack Obama’s administration fall into place, one looming choice of great importance to the pharmaceutical and biotechnology industries is the choice of the next commissioner of the US Food and Drug Administration. A
President-elect Barack Obama is moving quickly in selecting former Senate majority leader Tom Daschle as the potential secretary of Health and Human Services. Daschle has been a close advisor to Obama and may now be the administration’s point person on moving health reform legislation through Congress. Reform advocates consider the selection a sign that the Obama administration will seek to fulfill its promises to make health reform a top priority.